Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105279 | 1.00 | KDM4E (0.48) | KDM4ETBXAS1PKMKMT2ANAPRT | |
| SCHEMBL4734008 | 0.85 | CYP1A2 (0.58) | CYP1A2GRIK1GRIK2 | |
| SCHEMBL2566762 | 0.81 | PKM (0.60) | KDM4ETBXAS1PKMKMT2ANAPRT | |
| SCHEMBL30660224 | 0.81 | PKM (0.60) | KDM4ETBXAS1PKMKMT2ANAPRT | |
| SCHEMBL7384333 | 0.80 | CYP1A2 (0.62) | KDM4ETBXAS1PKMKMT2ANAPRT | |
| SCHEMBL21896075 | 0.76 | TBXAS1 (0.56) | KDM4ETBXAS1PKMKMT2ANAPRT | |
| SCHEMBL20366127 | 0.75 | CPA1 (0.67) | KDM4ETBXAS1NAPRTANPEPERAP2 | |
| SCHEMBL5051173 | 0.74 | PKM (0.49) | KDM4ETBXAS1PKMKMT2ANAPRT | |
| SCHEMBL30127868 | 0.73 | TBXAS1 (0.50) | KDM4ETBXAS1PKMKMT2ANAPRT | |
| SCHEMBL5060427 | 0.73 | TBXAS1 (0.53) | KDM4ETBXAS1PKMKMT2ANAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8753652-B2 | Pharmaceutical composition including a DHA ester to be administered parenterally | PIERRE FABRE MEDICAMENT (FR) | 2014-06-17 | — | — | US | disclosed |
| US-20120141563-A1 | PHARMACEUTICAL COMPOSITION INCLUDING A DHA ESTER TO BE ADMINISTERED PARENTERALLY | PIERRE FABRE MEDICAMENT (FR) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141563-A1 | PHARMACEUTICAL COMPOSITION INCLUDING A DHA ESTER TO BE ADMINISTERED PARENTERALLY | LIPA, ALOX5, ALOX15B | KDM4E 4379/4885TBXAS1 381/4885PKM 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.